Abstract This retrospective study investigates the correlation of intra-individual HER2 status between primary breast cancers and corresponding recurrences in a population derived cohort. The REMARK criteria were used as reference. In 151 breast cancer patients, primary tumors were analyzed for HER2 status on histopathology sections using immunohistochemistry (IHC) confirmed by fluorescence in situ hybridization (FISH) for IHC 2? and 3?. Recurrences (loco regional and distant) were investigated by aspiration cytology, using HER2 immunocytochemistry (ICC) or FISH (ICC in 84 patients and FISH in 102 patients). In the 151 patients, sites of recurrence were bone/ bone marrow 30%, liver 16%, local recurrence 18%, lung/ pleura 10%, axillary lymph nodes 9%, skin (non-local) 7%, supra clavicular lymph nodes 5%, and other sites 7%. In 15 patients (10%) HER2 status changed, 7 of 108 patients (6%) from HER2 negative to HER2 positive and 8 of 43 (19%) from HER2 positive to HER2 negative. Intra-patient agreement in HER2 status was 76% (95% CI 64-87%), and the disagreement was 10% (95% CI 5-15%). The multivariable Cox analysis showed a significantly increased risk of dying in the patient group with changed HER2 status compared to patients with concordant positive HER2 status. Overall survival HR is 5.47 (95% CI 2.01-14.91) and survival from relapse HR is 3.22 (95% CI 1.18-8.77). The unstable status for HER2 in breast cancer is clinically significant and should motivate more frequent testing of recurrences.
Introduction
Knowledge of the human epidermal growth factor receptor 2 HER2/neu (HER2) status is required for correct management of breast cancer patients, as the HER2 status is an independent prognostic factor [1, 2] and a predictor of response to treatment with the HER2 monoclonal antibody trastuzumab. In HER2 positive metastatic breast cancer (MBC), response rates are 50-61% in combination with chemotherapy, resulting in significant prolonged time to progression and overall survival [3, 4] . In early breast cancer, the 3-year results showed 12% absolute overall survival benefit for trastuzumab treatment. The hazard ratio (HR) for death after 5 years follow-up was 0.63 for the trastuzumab-treated group compared to controls, and the absolute disease-free survival gain at 5 years was 9% [5] .
In the early studies, *30% of primary tumors showed HER2 gene amplification. This high percentage was most probably due to the fact that data were derived from patients with high-risk disease, patients with metastatic disease, or deceased patients [2] . Recent, population-based data (in a mammography screening environment) have shown that 14% of primary tumors have positive HER2 status [6] . HER2 status has generally been presumed to be stable during disease progression, even though this question has in previous studies not been properly addressed. Some studies have revealed intra-individual discordance in HER2 status between primary tumors and sites of relapse [7, 8] . A large retrospective study of triple negative disease, based on 789 patients, showed intra-individual discordance regarding HER2 status of 13.6% [9] . One study showed good correlation (97%) in HER2 status between primary breast cancer and circulating tumor cells, collected at the same time point. That study also reported that out of 24 patients with HER2 negative primary tumors and circulating tumor cells, 9 later developed HER2 gene amplification in circulating tumor cells during tumor disease progression [10] . Despite these previous observations, HER2 status from primary cancers is generally used in the management of metastatic disease, assuming stability of HER2 status during tumor progression.
HER2 status is determined by immunohistochemistry (IHC) or immunocytochemistry (ICC). There are several FDA approved HER2 kits (Dec 2008: Ventana, Durham, NC, USA; DAKO Glostrup, Denmark; Chromavision, San Juan Capistrano, CA, USA; Applied Imaging, Santa Clara, CA, USA; Bayer, Tarrytown, NY, USA). The fluorescence in situ hybridization (FISH) method is considered as the reference method. Today, FISH is used in selected cases only (IHC 2? and 3? in Sweden), mainly because it is more expensive and time consuming compared to IHC. One study demonstrated sensitivity of IHC 2-3? of 92.6%, and a specificity of IHC 3? of 98.8%, compared with FISH [11] .
The aim of the present study was to investigate the intraindividual correlation of HER2 status between primary breast cancer tumors and corresponding recurrences.
Materials and methods
This retrospective study was reported in accordance with the REMARK criteria [12] . Morphological verification of recurrent lesions, mostly using Fine Needle Aspirate (FNA) cytology, is routine at our department, Radiumhemmet, at the Karolinska University Hospital, as verification of all clinical and/or X-ray diagnosed breast cancer recurrences. Whenever possible, the samples are analyzed for HER2 status, in addition to morphology, hormone receptor status, and proliferation (Ki-67). For the present study, we use data from The Breast Cancer Registry, established in 1976, for the Stockholm-Gotland region to identify breast cancer patients with relapse (using the individually unique 10-digit id-number given to all newborn individuals in Sweden and to immigrants) during the time period January 1, 1997 The recurrence with HER2 status results was included (mainly the first recurrence).
Results are presented in three groups: unchanged HER2 negative status, unchanged HER2 positive status, and changed HER2 status (both positive to negative and negative to positive from primary tumor to recurrence).
The study was approved by the ethical committee at Karolinska Institutet, Stockholm.
Statistical methods
The agreement between assessments was calculated as the proportion of exact agreements or by taking chance into account, by the kappa statistics. Kappa categories according to Landis and Koch were used [13] .
Follow-up started at the date of breast cancer diagnosis and continued either until the date of death occurred or until the individual was censored (end of follow-up of December 31, 2007). Univariate analyses of survival (from breast cancer diagnosis to death, or censoring and recurrence to death or censoring) in women by use of the Kaplan-Meier method.
The risk of dying was modeled by use of a multivariable proportional hazards (Cox) model, adjusting for age, year of diagnosis, estrogen and progesterone receptor status, and clinical stage. The model was not adjusted for histological grade due to too many missing data ([70%). See Table 2 for missing variables. The proportional hazard assumption for the main exposure variable was assessed using Schoenfeld's test statistics [14] ; no significant deviation was noted. An arbitrary level of 5% statistical significance was used, presenting 95% confidence intervals (CI).
Results

Patient-related results
The study-based cohort consisted of a total of 1,181 breast cancers patients with recurrent disease at the Karolinska University Hospital (also diagnosed at St Goran hospital) and reported to the Regional Cancer Registry for the Stockholm-Gotland Health Care region during the time period January 1, 1997, to December 31, 2007 (total sample). At Radiumhemmet, the Karolinska University Hospital, FNA samples which included HER2 status were analyzed in 368 patients. In 151 of these patients, HER2 status was available on both primary tumor and a recurrent lesion (42 patients with primary tumor diagnosis at St Goran hospital and recurrence diagnosis at Radiumhemmet, the Karolinska University hospital).
Sites of recurrence were bone/bone marrow 43 (30%), liver 24 (16%), local recurrence 27 (18%), lung or pleura 15 (10%), axillary lymph nodes 13 (9%), skin (not local) 10 (7%), supra clavicular lymph nodes 8 (5%), and other sites 11 (7%). The patient flow is shown in Fig. 1 , and Table 1 demonstrates distribution of recurrent sites, as well as HER2 status and analysis method, in primary cancers and corresponding recurrences.
Patient and tumor characteristics at first diagnosis are presented in Table 2 . Twenty-four percent (24%) of patients in the group with unchanged HER2 negative status, and 6% of the patients with a change in HER2 status had triple negative primary breast cancer.
IHC analyses were carried out on 144 primary tumors, with 86 verified by FISH. In the recurrence samples, the corresponding numbers were 84 for ICC and 102 for FISH. See Table 1 for HER2 status and analysis method in primary tumors and recurrences.
Overall survival (OS) from diagnosis to death/censoring date and survival from recurrence (RS) to death/censoring date was analyzed by use of Kaplan-Meier graphs of the three groups (unchanged positive HER2 status, unchanged negative HER2 status, and changed HER2 status). The analyses indicated possible differences between the two HER2 stable groups and the change group (log rank test OS 0.55 and RS 0.04), see Figs. 2 and 3. One patient was excluded from the survival analyses due to missing relapse date, and 3 patients were excluded due to relapse after censoring date, 2 patients in the stable negative group, 1 patient in the stable positive group, and 1 patient in the change group. In order to further test this possible difference, in survival by group, a multivariate (Cox) model was used, adjusting for age and year of diagnosis, estrogen and progesterone receptor status. In the adjusted survival model, women with changed HER2 status had an increased hazard ratio (HR) for dying compared to women with concordant positive HER2 status, HR 5.47 (95% CI 2.01-14.91) for OS and HR 3.22 (95% CI 1.18-8.77) for RS (Table 3) .
HER 2 results
There were 43 (28%) HER positive primary tumors (IHC 3? and/or FISH amplified) and 41 (27%) HER2 positive recurrences (IHC 3? and/or FISH amplified).
In 15 patients (10% of the study population), HER2 had changed during the course of the disease. In 7 patients, out of 108 (6% of HER2 negative primary tumors), tumors changed from HER2 negative to HER2 positive, and in 8 out of 43 (19% of HER2 positive primary tumors), tumors changed from HER2 positive to HER2 negative ( Table 4) .
The kappa correlation in HER2 between primary tumors and recurrences was 76% (95% CI 64-87%), and the discordance between primary tumors and recurrences was 10% (95% CI 5-15%). Of the 43 patients with HER2 positive primary tumors, 33 patients (77%) received treatment with trastuzumab, 4 patients in the adjuvant setting, and 27 patients for recurrence disease (starting dates of trastuzumab not known for 2 patients).
Of the 42 patients with HER2 positive metastatic disease, 32 patients (76%) received trastuzumab treatment. All patients received trastuzumab for recurrent disease, although for 2 patients the start date for trastuzumab treatment was not known.
Of the 35 patients with unchanged HER2 positive status, 30 patients (86%) received therapy including trastuzumab, 4 patients in the adjuvant setting, and 23 patients for recurrent disease (starting dates not known for 3 patients receiving trastuzumab). Of the 15 patients with change in HER2 status, 5 (33%) received trastuzumab. See also Fig. 1 , Tables 2 and 4 .
Discussion
Our data show discordance in HER2 status between primary tumor and recurrent sites in 6% of primary HER2 negative tumors and 19% in primary HER2 positive cancers, which reflect a discordance of 10% for the entire study population of 151 individuals with paired samples. More important, the multivariable analysis revealed, despite a small sample size, a significantly increased risk of dying for patients with changed HER2 status, compared to patients with unchanged positive HER2 status. More study patients received adjuvant chemotherapy, compared with the total sample (80% HER2 stable group, 63% in HER2 change group, 57% in HER2 change group, and 37% of total sample), indicating more aggressive primary tumors (Table 2 ). This is in line with a recent publication on neoadjuvant treatment with trastuzumab. In that study, the patients who retained a positive HER2 status had better prognosis compared with patients who changed HER2 status [15] . In the unchanged HER2 negative, unchanged HER2 positive, and in the changed HER2 groups, 55, 34, and 56%, respectively, received adjuvant endocrine therapy. From these data, one cannot conclude that the used adjuvant therapies drive alterations of HER2 status. In other studies, the discordance in HER2 status between primary tumor and recurrence varies from 50% (in CTC) down to 6% [7] [8] [9] [10] [16] [17] [18] . However, the data from studies based on CTC cannot be compared with standard morphological methods. The number of cases included is relatively small in all studies, except for one study published by Liedtke et al. (13.6% discordance in HER2 status). One study concluded that it is unnecessary to take aspirates on metastases, as the discrepancy between primary tumor and metastasis is below 10%, yet an 18-19% discordance rate between metastatic sites was shown in this study [18] . One small prospective study based on 16 patients with HER2 positive primary tumors described switch to HER2 negative metastatic disease in 37% of patients [17] . There are other data on change in tumor behavior between primary tumor and recurrence in the same patient. A meta-analysis on studies investigating hormone receptor analyses showed discrepancies between primary tumor and metastasis in the same patient [19] . Another small study showed interaction between HER2 status and estrogen receptor expression [20] . There are also data showing that HER2 status may change, related to previous hormonal treatment, even if the analyses in that study were carried out on circulating tumor cells [21] . We strongly believe that it is very important to identify these patients, as survival could be prolonged substantially for each patient and unnecessary over treatment might be avoided [3, 4] .
Technical factors could be one reason behind differences in HER2 results, as IHC analyses are more uncertain compared with FISH, with an increased risk of false positive results [22] . There are several studies showing that the testing technique is very important, as well as the training and skills of the laboratory staff [23, 24] . For this study, 86 and 102 of the primary tumor and metastatic samples, respectively, were analyzed with FISH, and this technique has higher sensitivity and specificity compared with IHC/ICC [22] . In order to increase the precision with our IHC/ICC determinations of HER2, they were always run with two or three antibodies. Each run also included cell line controls with well-known HER2 status (BT474 ICC 3?, MDA453 ICC 2?, RT4 ICC 1?, and 5637 0), [6] . Taken together, the HER2 analyses have been carried out with optimal techniques and appropriate validation systems, which should enhance the value of the present study. As pointed out above, IHC/ICC is a less robust method; 92.6% sensitivity and 98.8% specificity compared to FISH [11] . Thus, we also analyzed the kappa correlation for the separate methods. The results of FISH, IHC/ICC, or a mix of both (either FISH or IHC/ICC in primary tumor or recurrence) were 74% (95% CI 59-90%) 100% (95% CI 100-100%), and 58% (95% CI 27-89%), respectively. If the analyses carried out with a mix of either (FISH or IHC/ ICC in primary tumor or relapse) were excluded, the kappa correlation was 81% (95% CI 69-93%). The kappa correlation of the entire study population was 76% (95% CI 64-87%).
This study is retrospective, as well as most of the other studies, and the level of evidence is therefore regarded as lower compared with prospective data. Biopsy verification of recurrences was previously not standard procedure in the Stockholm-Gotland region at any other hospital. In 1999, we started to morphologically verify recurrences at Karolinska University hospital, Radiumhemmet; thereby we found single patients with non-breast cancer recurrences, and if the material contained enough cells we aimed at analyzing, HER2, estrogen-and progesterone receptors, and Ki-67 (MIB-1). There were 1,181 metastatic patients reported to the cancer registry, 368 tumor samples with HER2 status results on recurrences, and there were 151 HER2 status results on primary tumors with corresponding HER2 analysis in any recurrence. Of the total 1,181 patients, 669 had the primary diagnosis before 1999, and subsequent testing of selected primary tumors was performed on stored tumor samples. All of this means that there is a selection of the present study sample. The characteristics of the total sample (1021 excluding the study sample) and the study sample (151) are listed in Table 2 . Data in this table show that the study population is younger (indicating less frequent morphological confirmation of relapse of older patients), has shorter time to progression, and as expected, a larger proportion of study patients who received adjuvant chemotherapy (more aggressive disease).
Our findings do not indicate that there is a change in HER2 status related to site of relapse (Tables 1, 4 ). Tumor cell heterogeneity has been observed in some series and could explain discordances in HER2 status between primary tumor and recurrence [25, 26] . According to Wu et al. primary tumors, as well as recurrences, are heterogeneous, with foci with variable morphology and marker expressions. Our group could not verify this claimed intra-tumor heterogeneity in a study of 78 invasive cancers, although in situ components complicated the picture, and one cancer demonstrated heterogeneity [27] . Based on these somewhat contradictory results, cancers are either heterogeneous for HER2 status, or different clone expansions may explain the changed findings in recurrent lesions compared with the primary cancer. A Danish study shows that ductal carcinoma in situ of comedo type has high HER2 positivity and is homogeneous for HER2. In that study, the corresponding invasive cancers have lower levels of HER2 alterations, indicating that some HER2 (in situ) cancers can loose their HER2 characteristics [28] . In addition, we have in a previous study demonstrated that new and further p53 mutations can occur in the metastatic lesions compared with the primary cancers [29] . More recently, data show that single nucleotide mutational heterogeneity can be a property of low or intermediate grade primary breast cancers and that significant evolution can occur with disease progression (only 5 of the 32 mutations in the metastasis were found in the primary tumor), and the HER2 gene was amplified in the metastasis, but not in the primary tumor [30] .
The conclusion of our study is that a number of patients, who experience a recurrence, will not be managed correctly, if therapy is only based on characteristics of the primary tumor. The oncogene HER lacks stability during tumor progression and this should imply more frequent testing of recurrences. 
